Biochemical-Cellular crosstalk in diabetes: exploring pathways driving microvascular complications.

Diabetes mellitus continues to be a significant global health challenge, with microvascular complications like retinopathy, nephropathy, and neuropathy being major contributors to long-term illness and disability. When blood sugar levels remain high, it sets off a complicated series of biochemical reactions, including the activation of pathways like the polyol and hexosamine pathways, the buildup of advanced glycation end-products (AGEs), protein kinase C (PKC) activation, and increased oxidative stress, that collectively disrupt cellular homeostasis. These biochemical changes affect crucial cell types such as endothelial cells, pericytes, podocytes, Schwann cells, and neurons, leading to structural and functional damage that ends up with vascular leakage, thickening of the basement membrane, and problems with neurovascular functions. On a molecular level, pro-inflammatory cytokines (like TNF-α, IL-1β, and IL-6), chemokines (MCP-1), adhesion molecules (like VCAM-1, and ICAM-1), and profibrotic factors (such as VEGF, TGF-β, and Periostin), along with various intracellular signaling pathways (including NF-κB, AMPK, RANKL, Caspass-3, and JAK/STAT), perpetuate inflammation, cellular adhesion, angiogenesis, and fibrosis. Complex biochemical and signaling pathways are increasingly implicated in the persistence of metabolic memory, leading to distinct cellular changes as well as dysfunction in tissues and organs, ultimately resulting in disease progression. The clarification and broadening of the metabolic memory concept offer a deeper understanding of the pathogenic mechanisms involved in metabolic diseases and their complications, paving the way for comprehensive studies as potential new treatment approaches. This review sheds light on the complex biochemical, cellular, and molecular processes that lead to microvascular damage, and it aims to create a comprehensive framework for discovering new biomarkers and treatment targets. A multifaceted strategy that addresses these common pathways could be key to preventing or reducing the impact of diabetic microvascular complications.